Accession Number : ADB160958

Title :   Development of Dengue Vaccine. Phase 2.

Descriptive Note : Final rept. 15 Sep 89-14 Sep 90,

Corporate Author : HAWAII BIOTECHNOLOGY GROUP INC AIEA

Personal Author(s) : Ivy, John M.

Report Date : 15 DEC 1990

Pagination or Media Count : 29

Abstract : Work has been in four areas: subcloning of NS1, characterization of anti-D3 human sera, subcloning of E, and expression of dengue proteins/peptides. Four HaeIII fragments subclones in lambda gtll have been identified in the correct orientation: Hae272, Hae166, Hae415 and Hae113. Alterations in the Western protocol have resulted in successful Western analysis with human sera. Several attempts to subclone various large fragments of the E gene into pSS20 have been unsuccessful. Lysogens of the complete NS1 gene and a truncated E have been generated and shown to produce the expected fusion proteins.

Descriptors :   BLOOD SERUM, DENGUE, FRAGMENTS, GENES, HUMANS, PEPTIDES, PROTEINS, TRUNCATION, VACCINES.

Subject Categories : Genetic Engineering and Molecular Biology
      Pharmacology

Distribution Statement : APPROVED FOR PUBLIC RELEASE